EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Tezacaftor is a direct inhibitor of sphingolipid delta-4 desaturase enzyme (DEGS)

Dinu Zinovie Ciobanu, Nara Liessi, Valeria Tomati, Valeria Capurro, Sine Mandrup Bertozzi, Maria Summa, Rosalia Bertorelli, Nicoletta Loberto, Dorina Dobi, Massimo Aureli, Lucilla Nobbio, Tiziano Bandiera und 3 weitere

Journal of Cystic Fibrosis · 2024-11 · 23 (6) · 1167-1172

DOI: 10.1016/j.jcf.2024.05.004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2024-11. Verfasst von Dinu Zinovie Ciobanu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Analytical Chemistry Facility, Istituto Italiano di Tecnologia, Via Morego 30, 16163, Genova, Italy. Hauptthemen laut MEDLINE: Aminophenols, Benzodioxoles, Indoles. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministero della Salute, Fondazione per la Ricerca sulla Fibrosi Cistica.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: We recently demonstrated that 48 h exposure of primary human bronchial epithelial (hBE) cells, obtained from both CF (F508del homozygous) and non-CF subjects, to the triple drug combination Elexacaftor/Tezacaftor/Ivacaftor (ETI) results in a CFTR genotype-independent modulation of the de novo synthethic pathway of sphingolipids, with an accumulation of dihydroceramides (dHCer). Since dHCer are converted into ceramides (Cer) by the action of a delta-4 sphingolipid desaturase (DEGS) enzyme, we aimed to better understand this off-target effect of ETI (i.e., not related to CFTR rescue) METHODS: hBE cells, both F508del and wild-type, were cultured to create fully differentiated bronchial epithelia. We analyzed Cer and dHCer using an LC-MS based method previously developed by our lab. DEGS expression levels in differentiated hBE cells lysates were quantified by western blot analysis. RESULTS: We demonstrated that 1) dHCer accumulate in hBE with time following prolonged ETI exposure, that 2) similar inhibition occurs in wild-type primary human hepatocytes and that 3) this does not result in an alteration of DEGS expression. We then proved that 4) ETI is a direct inhibitor of DEGS, that 5) Tezacaftor is the molecule responsible for this effect, that 6) the inhibition is concentration dependent. Finally, after repeated oral administration of ETI to naïve, non-CF, mice, we observed a slight accumulation of dHCer in the brain. CONCLUSIONS: We believe that further investigations on Tezacaftor should be envisaged, particularly for the use of ETI during pregnancy, breastfeeding and in the early stages of development. DEGS dysfunction and dHCer accumulation causes impairment in the development of the nervous system, due to a derangement in myelin formation and maintenance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AminophenolsBenzodioxolesIndolesHumansMiceAnimalsPyrazolesQuinolonesCells, CulturedCystic FibrosisEpithelial CellsBronchiOxidoreductasesCystic Fibrosis Transmembrane Conductance RegulatorCeramidesPyridinesPyrrolidines

Stichwörter der Autor:innen

Cystic fibrosisDihydroceramidesETIMyelinTezacaftor

Substanzen

AminophenolsBenzodioxolestezacaftorIndolesPyrazolesQuinolonesivacaftordihydroceramideelexacaftorOxidoreductases

Autor:innen und Institutionen

  • Analytical Chemistry Facility, Istituto Italiano di Tecnologia, Via Morego 30, 16163, Genova, Italy.
  • UOC Genetica Medica, IRCCS Istituto Giannina Gaslini, Via Gerolamo Gaslini 5, 16147, Genova, Italy.
  • Translational Pharmacology Facility, Istituto Italiano di Tecnologia, Via Morego 30, 16163, Genova, Italy.
  • Dipartimento di Biotecnologie Mediche e Medicina Traslazionale, Università degli Studi di Milano, Via F.lli Cervi 93, 20054, Segrate, Milano, Italy.
  • IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132, Genova, Italy.
  • D3 PharmaChemistry, Istituto Italiano di Tecnologia, Via Morego 30, 16163, Genova, Italy.

Förderung

  • Ministero della Salute
  • Fondazione per la Ricerca sulla Fibrosi Cistica

Zitieren

APA

Ciobanu, D. Z., Liessi, N., Tomati, V., Capurro, V., Bertozzi, S. M., Summa, M., Bertorelli, R., Loberto, N., Dobi, D., Aureli, M., Nobbio, L., Bandiera, T., Pedemonte, N., Bassi, R., & Armirotti, A. (2024). Tezacaftor is a direct inhibitor of sphingolipid delta-4 desaturase enzyme (DEGS). Journal of Cystic Fibrosis, 23(6), 1167-1172. https://doi.org/10.1016/j.jcf.2024.05.004

Vancouver

Ciobanu DZ, Liessi N, Tomati V, Capurro V, Bertozzi SM, Summa M, et al. Tezacaftor is a direct inhibitor of sphingolipid delta-4 desaturase enzyme (DEGS). Journal of Cystic Fibrosis. 2024;23(6):1167-1172. doi:10.1016/j.jcf.2024.05.004

BibTeX
@article{Ciobanu2024,
  author = {Ciobanu, Dinu Zinovie and Liessi, Nara and Tomati, Valeria and Capurro, Valeria and Bertozzi, Sine Mandrup and Summa, Maria and Bertorelli, Rosalia and Loberto, Nicoletta and Dobi, Dorina and Aureli, Massimo and Nobbio, Lucilla and Bandiera, Tiziano and Pedemonte, Nicoletta and Bassi, Rosaria and Armirotti, Andrea},
  title = {Tezacaftor is a direct inhibitor of sphingolipid delta-4 desaturase enzyme (DEGS)},
  journal = {Journal of Cystic Fibrosis},
  year = {2024},
  volume = {23},
  number = {6},
  pages = {1167--1172},
  doi = {10.1016/j.jcf.2024.05.004}
}
Kostenlos starten →